Evogene (EVGN) Tax Provisions (2016 - 2026)

Evogene (EVGN) posted Tax Provisions of $4000.0 for Q1 2026, up 157.14% sequentially from -$7000.0 in Q4 2025.

Evogene (EVGN) Tax Provisions (2016 - 2026) Analysis & Trends

Evogene has reported Tax Provisions for 11 years, with the latest figure at $4000.0 in Q1 2026.

Quarterly Tax Provisions changed N/A year-over-year to $4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4000.0 (changed N/A YoY) and the FY2025 annual result came in at -$6000.0, down 166.67% from the prior year.
Tax Provisions climbed to $4000.0 in Q1 2026 per EVGN's latest filing, from -$7000.0 in the prior quarter.
Over five years, Tax Provisions peaked at $45000.0 in Q4 2022 and troughed at -$45000.0 in Q1 2023.
A 5-year average of $5166.7 and a median of $3000.0 in 2022 frame the typical range for Tax Provisions.
The sharpest annual moves came in 2022 and 2023: Tax Provisions soared 1166.67% in 2022, then tumbled 2350.0% in 2023.
Over 5 years, Tax Provisions stood at $45000.0 in 2022, then plunged by 108.89% to -$4000.0 in 2023, then surged by 275.0% to $7000.0 in 2024, then slumped by 200.0% to -$7000.0 in 2025, then surged by 157.14% to $4000.0 in 2026.
According to Business Quant data, Tax Provisions over the past three periods registered $4000.0, -$7000.0, and $7000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	4,000.00

Download Data